FDA Responds to MRA on Confidentiality of Respondent Data in Marketing Research - Articles

Articles

Stay at the forefront of the consumer insights and analytics industry with our Thought Leadership content. Here you’ll find timely updates on the Insights Association’s advocacy efforts, including the latest legislative and regulatory developments that impact how we work. In addition, this section offers expert perspectives on innovative research techniques and methodologies, as well as valuable analysis of evolving consumer trends. Together, these insights provide a trusted resource for professionals looking to navigate change, elevate their practice, and shape the future of our industry.

FDA Responds to MRA on Confidentiality of Respondent Data in Marketing Research

AUTHOR: LATOYA LANG

The Food and Drug Administration (FDA) has responded to MRA on our concerns regarding the confidentiality of marketing research data.

"FDA appreciates the concerns raised by MRA, and agrees with the importance of protecting the confidentiality of personal privacy information, including personally identifiable information, of those persons who participate in consumer surveys or other marketing research. Similarly, FDA understands the importance of protecting confidential commercial information, including trade secret and proprietary information."

MRA had contacted the FDA regarding the agency's sweeping demands for marketing research documents from Phillip Morris USA, Inc. to share our concerns about the need to keep respondents' personal information private and not jeopardize the research process or research trade secrets.

Read the FDA's response.

Attachments

  1. fda_response_to_mra_10-22-2010.pdf 6/28/2022 9:20:11 PM

Related

Share

Login

Members only Article - Please login to view
  • Back to top